ROIVRoivant Sciences Ltd.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Price is +20% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 7.9% since the previous count, up from 4.6% of shares outstanding three months ago.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ROIV is trading
Roivant Sciences Ltd. is +136% over the past year while the S&P 500 is +18%: 117 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +20%
vs 200-day average · a clear uptrend
- RSI (14)
- 31
RSI (14) · neutral
- Below its 52-week high
- 15%
Below its 52-week high
Details›
- Last close2026-10-09
- $35.42
- 1 monthS&P 500 +2.7%
- −13%
- 1 yearS&P 500 +18%
- +136%
- 5 yearsS&P 500 +88%
- +255%
- vs 50-day average$36.63
- −3.3%
- 52-week high
- $41.81
- 52-week low
- $14.70
- Annualised volatility
- 40%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$234M
| Year | Return |
|---|---|
| 2026 (year to date) | +63% |
| 2025 | +83% |
| 2024 | +5.3% |
| 2023 | +41% |
| 2022 | −21% |
| 2021 | −0.88% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 2 of 6 | −7.2% |
| Feb | 6 | 2 of 6 | +5.3% |
| Mar | 6 | 0 of 6 | −8.8% |
| Apr | 6 | 5 of 6 | +2.2% |
| May | 6 | 3 of 6 | +3.5% |
| Jun | 6 | 5 of 6 | +3.5% |
| Jul | 6 | 4 of 6 | +3.3% |
| Aug | 6 | 4 of 6 | +1.1% |
| Sep | 6 | 3 of 6 | +2.0% |
| Oct | 6 | 3 of 6 | +7.9% |
| Nov | 5 | 4 of 5 | +2.5% |
| Dec | 5 | 4 of 5 | +23% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
Ranks #19 of 196 by RyuScore